Angiotensin (1-7)

What Is Angiotensin (1-7)?

Angiotensin (1-7) is a heptapeptide of the renin-angiotensin system (RAS) that acts through the MAS receptor. It is the counter-regulatory peptide to angiotensin II — while Ang II promotes vasoconstriction, inflammation, fibrosis, and tissue damage, Ang(1-7) promotes vasodilation, anti-inflammation, anti-fibrosis, and tissue protection.

Ang(1-7) is produced by the enzyme ACE2 (angiotensin-converting enzyme 2) from angiotensin II. ACE2 gained widespread recognition as the receptor for SARS-CoV-2 (COVID-19). The virus's binding to ACE2 reduces Ang(1-7) production, shifting the RAS balance toward the harmful Ang II pathway — potentially explaining some COVID-19 pathology.

Therapeutic administration of Ang(1-7) aims to restore the protective RAS balance — reducing inflammation, fibrosis, and organ damage while improving cardiovascular function. This approach has attracted significant research interest for cardiovascular disease, pulmonary fibrosis, kidney disease, and post-COVID syndromes.

What The Research Says

Preclinical studies demonstrate Ang(1-7) reduces blood pressure, decreases cardiac fibrosis, protects against stroke, improves renal function, and reduces pulmonary inflammation. In diabetic models, it improves insulin sensitivity and reduces end-organ damage.

The COVID-19 pandemic accelerated Ang(1-7) research: clinical trials explored Ang(1-7) (as TXA127) for COVID-19 respiratory failure with preliminary positive results. Post-COVID syndrome studies are ongoing. The fundamental RAS physiology supporting this approach is well-established.

📚 Key Reference: PMID: 17306030 (Ang(1-7) cardiovascular), PMID: 32979938 (COVID-19 RAS)

Common Uses

• Cardiovascular protection (research)
• Pulmonary fibrosis (research)
• Post-COVID syndrome (investigational)
• Kidney protection (research)
• Anti-fibrotic therapy (research)
• Metabolic health (research)

Important Safety Information

Hypotension is the primary concern due to vasodilatory effects. Short half-life limits prolonged effects. Preclinical safety is favorable. Human clinical trial data is emerging. Consult your provider.

Questions To Ask Your Provider

1. What specific cardiovascular or inflammatory condition is being treated?
2. What blood pressure monitoring will be in place?
3. What is the evidence level for my condition?

Regulatory Status

NOT FDA-approved. TXA127 (clinical-grade Ang(1-7)) has been studied in clinical trials. Research use only outside of trials.